Randomized controlled trial of whole soy and isoflavone daidzein on menopausal symptoms in equol-producing Chinese postmenopausal women

Liu, Zhaomin; Ho, Suzanne C.; Woo, Jean; Chen, Yuming; Wong, Carmen

doi:10.1097/gme.0000000000000102

Cited by 38 publications

(44 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies of soy isoflavones (de Sousa‐Munoz & Filizola, ), whole soy, and daidzein (Liu, Ho, Woo, Chen, & Wong, ) failed to find any reductions in depressive symptoms.…”

Section: Resultsmentioning

confidence: 99%

Herbal medicine for depression and anxiety:Asystematic review with assessment of potential psycho‐oncologic relevance

Yeung

Hernandez

Mao

et al. 2018

Phytotherapy Research

176

100

View full text Add to dashboard Cite

Anxiety and depression are prevalent among cancer patients, with significant negative impact. Many patients prefer herbs for symptom relief to conventional medications which have limited efficacy/side effects. We identified single-herb medicines that may warrant further study in cancer patients. Our search included PubMed, Allied and Complementary Medicine, Embase, and Cochrane databases, selecting only single-herb randomized controlled trials between 1996 and 2016 in any population for data extraction, excluding herbs with known potential for interactions with cancer treatments. One hundred articles involving 38 botanicals met our criteria. Among herbs most studied (≥6 randomized controlled trials each), lavender, passionflower, and saffron produced benefits comparable to standard anxiolytics and antidepressants. Black cohosh, chamomile, and chasteberry are also promising. Anxiety or depressive symptoms were measured in all studies, but not always as primary endpoints. Overall, 45% of studies reported positive findings with fewer adverse effects compared with conventional medications. Based on available data, black cohosh, chamomile, chasteberry, lavender, passionflower, and saffron appear useful in mitigating anxiety or depression with favorable risk-benefit profiles compared to standard treatments. These may benefit cancer patients by minimizing medication load and accompanying side effects. However, well-designed larger clinical trials are needed before these herbs can be recommended and to further assess their psycho-oncologic relevance.

show abstract

“…Studies of soy isoflavones (de Sousa‐Munoz & Filizola, ), whole soy, and daidzein (Liu, Ho, Woo, Chen, & Wong, ) failed to find any reductions in depressive symptoms.…”

Section: Resultsmentioning

confidence: 99%

Herbal medicine for depression and anxiety:Asystematic review with assessment of potential psycho‐oncologic relevance

Yeung

Hernandez

Mao

et al. 2018

Phytotherapy Research

176

100

View full text Add to dashboard Cite

show abstract

“…Of these, 330 were excluded; 59 included fewer than 20 women per study arm and 54 were not an RCT; 126 did not clearly state a sample size calculation; 52 did not measure vasomotor symptoms as the primary outcome; 39 were secondary analysis. Following these exclusions, 214 RCT were included…”

Section: Resultsmentioning

confidence: 99%

“…However, they will still be used for the subsequent Delphi process. Other subjective vasomotor symptoms measurement tools included a 20‐item structured symptom checklist; two of the items asking about the presence of hot flushes and cold/night sweats, a 5‐point (from none to very severe) scoring system about the severity of hot flushes and night sweats, Interactive Voice Response System to record the number and severity of the hot flushes, and self‐reported surveys . Objective measures of vasomotor symptoms such as skin conductance were used in five trials in addition to subjective measures (Table ).…”

Section: Resultsmentioning

confidence: 99%

Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review

Iliodromiti

Wang

Lumsden

et al. 2019

BJOG

View full text Add to dashboard Cite

Background There is substantial variation in how menopausal vasomotor symptoms are reported and measured among intervention studies. This has prevented meaningful comparisons between treatments and limited data synthesis. Objectives To review systematically the outcome reporting and measures used to assess menopausal vasomotor symptoms from randomised controlled trials of treatments. Search strategy We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials from inception to May 2018. Selection criteria Randomised controlled trials with a primary outcome of menopausal vasomotor symptoms in women and a sample size of at least 20 women per study arm. Data collection and analysis Data about study characteristics, primary vasomotor‐related outcomes and methods of measuring them. Main results The search identified 5591 studies, 214 of which were included. Forty‐nine different primary reported outcomes were identified for vasomotor symptoms and 16 different tools had been used to measure these outcomes. The most commonly reported outcomes were frequency (97/214), severity (116/214), and intensity (28/114) of vasomotor symptoms or a composite of these outcomes (68/214). There was little consistency in how the frequency and severity/intensity of vasomotor symptoms were defined. Conclusions There is substantial variation in how menopausal vasomotor symptoms have been reported and measured in treatment trials. Future studies should include standardised outcome measures which reflect the priorities of patients, clinicians, and researchers. This is most effectively achieved through the development of a Core Outcome Set. This systematic review is the first step towards development of a Core Outcome Set for menopausal vasomotor symptoms. Tweetable summary Menopausal hot flushes and night sweats have been reported in 49 different ways in clinical research. A core outcome set is urgently required.

show abstract

“…Finally, results from a 6-month Chinese study from Hong Kong involving 270 postmenopausal equol-producing women who were divided into three groups: (1) 40 g/day soy flour, (2) 40 g/day low-fat milk powder + 63 mg of daidzein and (3) 40 g/day low-fat milk powder (placebo group) 42 found no differences in any of the menopausal symptoms assessed by a validated and structured symptom checklist among the groups.…”

Section: Clinical Researchmentioning

confidence: 99%

S-equol: A Potential Nonhormonal Agent for Menopause-Related Symptom Relief

Utian

Jones

Setchell

2015

Journal of Women's Health

View full text Add to dashboard Cite

Many women suffering from vasomotor symptoms (VMS) are now seeking nonpharmaceutical treatments for symptom relief. Recently, S-equol, an intestinal bacterial metabolite of the soybean isoflavone daidzein has received attention for its ability to alleviate VMS and provide other important health benefits to menopausal women. S-equol is found in very few foods and only in traces. About 50% of Asians and 25% of non-Asians host the intestinal bacteria that convert daidzein into S-equol. Clinical trials that evaluated the efficacy of an S-equol-containing product found that VMS were alleviated but these trials were limited in scope and primarily involved Japanese women for whom hot flashes are a minor complaint. The only trial in the United States evaluating hot flashes found symptoms were significantly reduced by S-equol, but the study lacked a placebo group, although it did include a positive control. The daily dose of S-equol used in most trials was 10 mg, and because the half-life of S-equol is 7-10 hours, to maximize efficacy, it was taken twice daily. Subanalysis of epidemiologic studies suggests that equol producers are more likely to benefit from soyfood consumption than nonproducers with respect to both cardiovascular disease and osteoporosis, although the data are inconsistent. The limited safety data for S-equol do not suggest cause for concern, especially with regard to its effects on breast and endometrial tissue. Further studies are needed before definitive conclusions of its effectiveness for VMS can be made, but the preliminary evidence warrants clinicians discussing the potential of S-equol for the alleviation of VMS with patients.

show abstract

Randomized controlled trial of whole soy and isoflavone daidzein on menopausal symptoms in equol-producing Chinese postmenopausal women

Abstract: Whole soy and purified daidzein have no significant effect on alleviation of menopausal symptoms among equol-producing postmenopausal women with prehypertension.

Cited by 38 publications

References 41 publications

Herbal medicine for depression and anxiety:Asystematic review with assessment of potential psycho‐oncologic relevance

Herbal medicine for depression and anxiety:Asystematic review with assessment of potential psycho‐oncologic relevance

Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review

S-equol: A Potential Nonhormonal Agent for Menopause-Related Symptom Relief

Contact Info

Product

Resources

About